It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.|

Human, Rat, Mouse

WB,ELISA

WB 1:500-2000
ELISA 1:10000-50000

human: q86vb7.2

Synthesized peptide derived from human C163A

Rabbit

Polyclonal

IgG

Immunology; Cardiovascular

Liquid

1mg/ml

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Store at +4℃ after thawing. For long-term storage, please store it at -20℃. Avoid repeated freeze / thaw cycles.